Vonoprazan fumarate is a novel acid-suppressing drug—a potassium-competitive acid blocker (P-CAB). By reversibly inhibiting H⁺, K⁺-ATPase activity in a potassium-competitive manner, vonoprazan remains in gastric parietal cells for an extended period, thereby inhibiting gastric acid production and effectively preventing mucosal damage in the upper gastrointestinal tract. Vonoprazan fumarate does not require acid activation, achieves full efficacy with the first dose, and provides rapid, potent, durable, and stable acid suppression. Its acid-inhibitory effect is not influenced by food intake, allowing administration either before or after meals, which enhances dosing convenience.

Primary Indications

Gastroesophageal reflux disease.

In combination with appropriate antibiotics to eradicate Helicobacter pylori.

The Main Contraindication To Medication

1. Contraindicated in patients with known hypersensitivity to any component of this product.

2. Contraindicated in patients receiving therapy with atazanavir or rilpivirine (see [Drug Interactions]).

3. For information on contraindications related to drugs used in combination with vonoprazan (clarithromycin, amoxicillin, and bismuth potassium citrate), please refer to the Contraindications section of their respective prescribing information.

Dosage Form

Tablet